1.Ovarian Cancer Prognostic Prediction Model Using RNA Sequencing Data
Seokho JEONG ; Lydia MOK ; Se Ik KIM ; TaeJin AHN ; Yong Sang SONG ; Taesung PARK
Genomics & Informatics 2018;16(4):e32-
Ovarian cancer is one of the leading causes of cancer-related deaths in gynecological malignancies. Over 70% of ovarian cancer cases are high-grade serous ovarian cancers and have high death rates due to their resistance to chemotherapy. Despite advances in surgical and pharmaceutical therapies, overall survival rates are not good, and making an accurate prediction of the prognosis is not easy because of the highly heterogeneous nature of ovarian cancer. To improve the patient's prognosis through proper treatment, we present a prognostic prediction model by integrating high-dimensional RNA sequencing data with their clinical data through the following steps: gene filtration, pre-screening, gene marker selection, integrated study of selected gene markers and prediction model building. These steps of the prognostic prediction model can be applied to other types of cancer besides ovarian cancer.
Drug Therapy
;
Filtration
;
Mortality
;
Ovarian Neoplasms
;
Prognosis
;
RNA
;
Sequence Analysis, RNA
;
Survival Rate
2.Long-Term Outcomes of Hemispheric Disconnection in Pediatric Patients with Intractable Epilepsy.
Yun Jeong LEE ; Eun Hee KIM ; Mi Sun YUM ; Jung Kyo LEE ; Seokho HONG ; Tae Sung KO
Journal of Clinical Neurology 2014;10(2):101-107
BACKGROUND AND PURPOSE: Hemispherectomy reportedly produces remarkable results in terms of seizure outcome and quality of life for medically intractable hemispheric epilepsy in children. We reviewed the neuroradiologic findings, pathologic findings, epilepsy characteristics, and clinical long-term outcomes in pediatric patients following a hemispheric disconnection. METHODS: We retrospectively studied 12 children (8 males) who underwent a hemispherectomy at Asan Medical Center between 1997 and 2005. Clinical, EEG, neuroradiological, and surgical data were collected. Long-term outcomes for seizure, motor functions, and cognitive functions were evaluated at a mean follow-up of 12.7 years (range, 7.6-16.2 years) after surgery. RESULTS: The mean age at epilepsy onset was 3.0 years (range, 0-7.6 years). The following epilepsy syndromes were identified in our cohort: focal symptomatic epilepsy (n=8), West syndrome (n=3), and Rasmussen's syndrome (n=1). Postoperative histopathology of our study patients revealed malformation of cortical development (n=7), encephalomalacia as a sequela of infarction or trauma (n=3), Sturge-Weber syndrome (n=1), and Rasmussen's encephalitis (n=1). The mean age at surgery was 6.5 years (range, 0.8-12.3 years). Anatomical or functional hemispherectomy was performed in 8 patients, and hemispherotomy was performed in 4 patients. Eight of our 12 children (66.7%) were seizure-free, but 3 patients with perioperative complications showed persistent seizure. Although all patients had preoperative hemiparesis and developmental delay, none had additional motor or cognitive deficits after surgery, and most achieved independent walking and improvement in daily activities. CONCLUSIONS: The long-term clinical outcomes of hemispherectomy in children with intractable hemispheric epilepsy are good when careful patient selection and skilled surgical approaches are applied.
Child
;
Chungcheongnam-do
;
Cohort Studies
;
Electroencephalography
;
Encephalitis
;
Encephalomalacia
;
Epilepsy*
;
Follow-Up Studies
;
Hemispherectomy
;
Humans
;
Infant
;
Infant, Newborn
;
Infarction
;
Paresis
;
Patient Selection
;
Quality of Life
;
Retrospective Studies
;
Seizures
;
Spasms, Infantile
;
Sturge-Weber Syndrome
;
Walking
3.CTHRC1 promotes angiogenesis by recruiting Tie2-expressing monocytes to pancreatic tumors.
Jaemin LEE ; Jinhoi SONG ; Eun Soo KWON ; Seongyea JO ; Min Kyung KANG ; Yeon Jeong KIM ; Yeonsil HWANG ; Hosung BAE ; Tae Heung KANG ; Suhwan CHANG ; Hee Jun CHO ; Song Cheol KIM ; Seokho KIM ; Sang Seok KOH
Experimental & Molecular Medicine 2016;48(9):e261-
CTHRC1 (collagen triple-helix repeat-containing 1), a protein secreted during the tissue-repair process, is highly expressed in several malignant tumors, including pancreatic cancer. We recently showed that CTHRC1 has an important role in the progression and metastasis of pancreatic cancer. Although CTHRC1 secretion affects tumor cells, how it promotes tumorigenesis in the context of the microenvironment is largely unknown. Here we identified a novel role of CTHRC1 as a potent endothelial activator that promotes angiogenesis by recruiting bone marrow-derived cells to the tumor microenvironment during tumorigenesis. Recombinant CTHRC1 (rCTHRC1) enhanced endothelial cell (EC) proliferation, migration and capillary-like tube formation, which was consistent with the observed increases in neovascularization in vivo. Moreover, rCTHRC1 upregulated angiopoietin-2 (Ang-2), a Tie2 receptor ligand, through ERK-dependent activation of AP-1 in ECs, resulting in recruitment of Tie2-expressing monocytes (TEMs) to CTHRC1-overexpressing tumor tissues. Treatment with a CTHRC1-neutralizing antibody-abrogated Ang-2 expression in the ECs in vitro. Moreover, administration of a CTHRC1-neutralizing antibody to a xenograft mouse model reduced the tumor burden and infiltration of TEMs in the tumor tissues, indicating that blocking the CTHRC1/Ang-2/TEM axis during angiogenesis inhibits tumorigenesis. Collectively, our findings support the hypothesis that CTHRC1 induction of the Ang-2/Tie2 axis mediates the recruitment of TEMs, which are important for tumorigenesis and can be targeted to achieve effective antitumor responses in pancreatic cancers.
Angiopoietin-2
;
Animals
;
Carcinogenesis
;
Endothelial Cells
;
Heterografts
;
In Vitro Techniques
;
Mice
;
Monocytes*
;
Neoplasm Metastasis
;
Pancreatic Neoplasms
;
Receptor, TIE-2
;
Transcription Factor AP-1
;
Tumor Burden
;
Tumor Microenvironment